The Roundtable Versus The Banquet Table
This article was originally published in RPM Report
Executive Summary
There will be extensive jockeying for attention over the next year from House Energy & Commerce Chairman Fred Upton for the “3D’s” review of drug legislation. NORD was not at the kick-off Capitol Hill roundtable but may already have the chairman’s ear -- or at least his emotional backing.
You may also be interested in...
Expanded Access Theme Is One Sour Note For Biopharma In “21st Century Cure” Roundtable
The Energy & Commerce Committee “21st Century Cures” Process promises to set a pro-innovation tone heading into the next user fee reauthorization cycle. There is one theme, however, that may be perilous for industry moving forward: Expanded Access.
US Price Negotiation Hearing Lays The Groundwork For Future Improvements
The pharma industry is hoping that litigation might end Medicare price negotiation before it begins. But a House hearing also starts the process of developing legislative improvements that might be viable in years to come – starting with trying to restore the lifespan of small molecules.
As Sickle Cell Gene Therapies Move To Market, Health Inequities Could Help Pricing Debate
Positive tandem ICER reviews for bluebird bio’s and Vertex/CRISPR’s gene therapies show the impact that concerns about addressing racial inequities could create a favorable context for products as they enter pricing and coverage discussions.